The study was performed by an independent laboratory, and it was the first study and data, that was looking for its effect against sub-variants or Omicron. Company decided to do this research, because of the global spike in cases again, with China seemingly took the worst hit.

The study was concluded with AstraZeneca’s drug Evusheld is lowering number of viruses in the lungs and it limited inflammation in the lungs – which is a critical symptom in severe COVID infections. Last week, WHO said that rising COVID cases are worrying, as countries are cancelling lockdowns and lowering the tests, that’s why this information is very important and welcomed, as Evusheld has also shown that it cuts the risk of developing symptomatic COVID by 77%. It was also shown that this drug saves lives and prevents disease progression when given within a week of first symptoms.

The difference between vaccine and Evusheld is that vaccines rely on an intact immune system to develop targeted antibodies, while Evusheld contains lab-made antibodies designed to stay in the body for months to contain the virus in case of an infection.

Movement of AstraZeneca´s stocks in the last 5 years